Skip to Content
Søk Menu

ASCO GU 2026: Adjuvant Belzutifan + Pembrolizumab Reduces Risk of Recurrence or Death in ccRCC

/ Jan Andreasen
ASCOGU26
Qiao Yang

Quantifying ER Expression: The Key to Personalizing Treatment in HER2-Negative ER-positive Breast Cancer

/ Qiao Yang
BröstcancerNBCNSABCS25 Play the Video
Fernando De Moura

ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

/ Fernando De Moura
ASCOGU26Prostatacancer Play the Video

Patient monitoring and decision-making in CIDP

/ Lars Kjøbsted Markvardsen / Jan Andreasen
CIDP

Evaluating Treatment Response in CIDP: Clinical Precision in a Heterogeneous Disorder

/ Aki Hietaharju / Jan Andreasen
CIDP

T-DXd in Patients with High-Risk HER2-Positive Early Breast Cancer – Are We Ready to Change Practice?

/ Henrik Lindman / Jan Andreasen
ESMO25

Combination of Enfortumab Vedotin and Pembrolizumab Has Radically Improved Bladder Cancer Treatment

/ Jakob Lauritsen / Jan Andreasen
Blåscancer

Disentangling IBD Associations with Other Immune-Mediated Diseases

/ Marie Vibeke Vestergaard
IBS Play the Video
Aleksandar Kostov

BRCA Testing in Denmark: Surgical Impact and Survival

/ Aleksandar Kostov
BröstcancerNBCN Play the Video

DESTINY-Breast11 and Neoadjuvant T-DXd: Insights from Finland

/ Maria Sundvall / Jan Andreasen
BröstcancerESMO25NBCN

BestPractice Nordic appoints Gitte Broholm as new Chief Commercial Officer

/ BestPractice Nordic

Lung Cancer Insights: What’s New in the Field – January Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungcancer
Hent flere
Back to top